Ahmed El‐Balat

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Jacobus Pfisterer, Catherine Shannon, Klaus Baumann et al. · The Lancet Oncology · 2020 · 162 citations

Medicine, Gynecology, Oncology +14

Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer

Thomas Karn, Tingting Jiang, Christos Hatzis et al. · JAMA Oncology · 2017 · 153 citations · Full text

Medicine, Cancer Biology, Oncology +17

Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)

Philipp Harter, Jan Hauke, Florian Heitz et al. · PLoS ONE · 2017 · 133 citations · Full text

Life Sciences, Genetics, Oncology +17

Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Radoslav Chekerov, Felix Hilpert, Sven� Mahner et al. · The Lancet Oncology · 2018 · 109 citations

Medicine, Oncology, Pharmacology +13

Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

Philipp Harter, Marie Ange Mouret-Reynier, Sandro Pignata et al. · Gynecologic Oncology · 2021 · 90 citations · Full text

Medicine, Oncology, Pharmacotherapy +17